256 related articles for article (PubMed ID: 25338019)
1. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.
Van der Jeught K; Joe PT; Bialkowski L; Heirman C; Daszkiewicz L; Liechtenstein T; Escors D; Thielemans K; Breckpot K
Oncotarget; 2014 Oct; 5(20):10100-13. PubMed ID: 25338019
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
[TBL] [Abstract][Full Text] [Related]
3. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.
Kim S; Buchlis G; Fridlender ZG; Sun J; Kapoor V; Cheng G; Haas A; Cheung HK; Zhang X; Corbley M; Kaiser LR; Ling L; Albelda SM
Cancer Res; 2008 Dec; 68(24):10247-56. PubMed ID: 19074893
[TBL] [Abstract][Full Text] [Related]
4. Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.
Ryzhov SV; Pickup MW; Chytil A; Gorska AE; Zhang Q; Owens P; Feoktistov I; Moses HL; Novitskiy SV
J Immunol; 2014 Sep; 193(6):3155-64. PubMed ID: 25127858
[TBL] [Abstract][Full Text] [Related]
5. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Huang F; Gonçalves C; Bartish M; Rémy-Sarrazin J; Issa ME; Cordeiro B; Guo Q; Emond A; Attias M; Yang W; Plourde D; Su J; Gimeno MG; Zhan Y; Galán A; Rzymski T; Mazan M; Masiejczyk M; Faber J; Khoury E; Benoit A; Gagnon N; Dankort D; Journe F; Ghanem GE; Krawczyk CM; Saragovi HU; Piccirillo CA; Sonenberg N; Topisirovic I; Rudd CE; Miller WH; Del Rincón SV
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690225
[TBL] [Abstract][Full Text] [Related]
7. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt SL; Bailey D; Zielinski J; Apte A; Musenge F; Karp R; Burke S; Garcon F; Mishra A; Gurumurthy S; Watkins A; Arnold K; Moynihan J; Clancy-Thompson E; Mulgrew K; Adjei G; Deschler K; Potz D; Moody G; Leinster DA; Novick S; Sulikowski M; Bagnall C; Martin P; Lapointe JM; Si H; Morehouse C; Sedic M; Wilkinson RW; Herbst R; Frederick JP; Luheshi N
Clin Cancer Res; 2020 Dec; 26(23):6284-6298. PubMed ID: 32817076
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
11. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
13. Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties.
Novitskiy SV; Pickup MW; Chytil A; Polosukhina D; Owens P; Moses HL
J Leukoc Biol; 2012 Sep; 92(3):641-51. PubMed ID: 22685318
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic immune response induced by electrofusion of dendritic and tumor cells.
Tanaka H; Shimizu K; Hayashi T; Shu S
Cell Immunol; 2002 Nov; 220(1):1-12. PubMed ID: 12718934
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy.
Van der Jeught K; Van Lint S; Thielemans K; Breckpot K
Oncoimmunology; 2015 May; 4(5):e1005504. PubMed ID: 26155403
[TBL] [Abstract][Full Text] [Related]
18. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
19. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization.
Kontani K; Kajino K; Huangi CL; Fujino S; Taguchi O; Yamauchi A; Yokomise H; Ogasawara K
Cancer Immunol Immunother; 2006 May; 55(5):579-87. PubMed ID: 16032398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
